Apparently, the Central Pharmaceutical Affairs Deliberation Committee has reached a conclusion after an intense discussion in approving of Celltrion’s COVID-19 monoclonal antibody treatment Rekirona, conditionally authorized for use on Feb. 5.

The Central Pharmaceutical Affairs Deliberation Committee was convened for a meeting on Jan. 27 and advised Rekirona to be conditionally used on high-risk patients with mild COVID-19 symptoms and patients with moderate symptoms. The indication was actually narrowed from the COVID-19 Treatment Advisory Panel’s previously opinion that the treatment can be used without a limitation in patients with mild to moderate symptoms.

In the Central Committ